Please check your internet connection and try again.
# Pandom DSR
## Overview
Pandom DSR is a fixed-dose combination product containing **Pantoprazole (40 mg)**, a proton pump inhibitor (PPI), and **Domperidone (30 mg)**, a dopamine (D2) receptor antagonist. It is formulated as a sustained-release (SR) capsule, primarily utilized to manage gastroesophageal reflux disease (GERD) and dyspeptic symptoms where both acid suppression and prokinetic activity are required.
## Primary Indications
* Gastroesophageal reflux disease (GERD).
* Non-ulcer dyspepsia.
* Motility-related gastric disorders (epigastric fullness, early satiety, nausea).
## Adult Dosing
* **Standard Dose:** 1 capsule (Pantoprazole 40 mg/Domperidone 30 mg) once daily.
* **Administration:** Taken orally, at least 30–60 minutes before the first meal of the day. The capsule must be swallowed whole; do not crush or chew.
## Pediatric Dosing
**Use is generally not recommended in children.** There is a lack of robust safety and efficacy data for the sustained-release combination in pediatric populations. Domperidone use in children is restricted globally due to the risk of cardiac arrhythmias.
## Dose Adjustments
* **Renal Impairment:** No initial dose adjustment for Pantoprazole is required. Domperidone dose may require reduction in severe renal impairment; consult local protocols.
* **Hepatic Impairment:** Pantoprazole dose should be reduced in severe liver disease (maximum 20 mg daily). Avoid or use with extreme caution in hepatic insufficiency.
## Contraindications
* Hypersensitivity to pantoprazole or domperidone.
* Existing prolongation of cardiac conduction intervals (specifically QTc).
* Underlying cardiac diseases (e.g., congestive heart failure, arrhythmias).
* Conditions where gastrointestinal motility stimulation is dangerous (e.g., GI hemorrhage, mechanical obstruction, perforation).
* Concomitant use of potent CYP3A4 inhibitors or drugs known to prolong QTc.
## Adverse Effects
* **Domperidone-related:** Dry mouth, headache, diarrhea, hyperprolactinemia (galactorrhea, gynecomastia), and serious cardiac arrhythmias (ventricular arrhythmias, sudden cardiac death).
* **Pantoprazole-related:** Vitamin B12 deficiency (long-term use), hypomagnesemia, *Clostridioides difficile*-associated diarrhea, and increased risk of fractures.
## Key Drug Interactions
* **QTc Prolonging Agents:** Increased risk of life-threatening arrhythmias.
* **Strong CYP3A4 Inhibitors:** (e.g., ketoconazole, clarithromycin, erythromycin) increase domperidone plasma concentrations.
* **pH-Dependent Drugs:** Pantoprazole reduces the absorption of drugs requiring acidic environments (e.g., atazanavir, ketoconazole, iron salts).
* **Warfarin:** Monitor INR closely, as PPIs may affect metabolism in some patients.
## Monitoring
* **Cardiac:** Baseline ECG recommended, especially in patients with cardiac risk factors.
* **Electrolytes:** Periodic monitoring of magnesium levels if used for >3 months.
* **Symptoms:** Evaluate clinical response; discontinue if symptoms resolve to prevent unnecessary long-term PPI use.
## Clinical Pearls
* **Cardiac Risk:** The addition of domperidone introduces a significant cardiovascular safety profile compared to pantoprazole monotherapy. Always evaluate the patient's cardiac history before prescribing.
* **Limited Duration:** Use the lowest effective dose for the shortest duration necessary to control symptoms.
* **Tapering:** Long-term PPI use should be tapered to avoid rebound acid hypersecretion.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice protocols vary by region. Always verify specific dosing and contraindications against the current local prescribing information (package insert) and hospital formulary before initiating therapy.
